vs
Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Picard Medical, Inc. (PMI). Click either name above to swap in a different company.
INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $1.2M, roughly 1.5× Picard Medical, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -878.3%, a 727.8% gap on every dollar of revenue.
INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.
IVF vs PMI — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8M | $1.2M |
| Net Profit | $-2.6M | $-10.4M |
| Gross Margin | — | -11.0% |
| Operating Margin | -93.1% | -293.8% |
| Net Margin | -150.5% | -878.3% |
| Revenue YoY | 22.6% | — |
| Net Profit YoY | -62.2% | — |
| EPS (diluted) | $-0.77 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.8M | $1.2M | ||
| Q2 25 | $1.9M | $2.1M | ||
| Q1 25 | $1.6M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $1.4M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $1.6M | — | ||
| Q4 23 | $1.4M | — |
| Q3 25 | $-2.6M | $-10.4M | ||
| Q2 25 | $-5.3M | $-6.7M | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q1 24 | $-1.6M | — | ||
| Q4 23 | $-2.0M | — |
| Q3 25 | — | -11.0% | ||
| Q2 25 | — | -6.0% | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 41.4% | — | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 53.1% | — | ||
| Q1 24 | 45.3% | — | ||
| Q4 23 | 33.0% | — |
| Q3 25 | -93.1% | -293.8% | ||
| Q2 25 | -160.4% | -165.2% | ||
| Q1 25 | -1042.1% | — | ||
| Q4 24 | -202.0% | — | ||
| Q3 24 | -90.7% | — | ||
| Q2 24 | -100.9% | — | ||
| Q1 24 | -95.7% | — | ||
| Q4 23 | -109.2% | — |
| Q3 25 | -150.5% | -878.3% | ||
| Q2 25 | -283.6% | -315.5% | ||
| Q1 25 | -1060.1% | — | ||
| Q4 24 | -211.3% | — | ||
| Q3 24 | -113.8% | — | ||
| Q2 24 | -122.2% | — | ||
| Q1 24 | -101.3% | — | ||
| Q4 23 | -144.4% | — |
| Q3 25 | $-0.77 | — | ||
| Q2 25 | $-13.30 | — | ||
| Q1 25 | $-12.53 | — | ||
| Q4 24 | $14.86 | — | ||
| Q3 24 | $-15.11 | — | ||
| Q2 24 | $-22.39 | — | ||
| Q1 24 | $-7.55 | — | ||
| Q4 23 | $-59.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.8M |
| Total DebtLower is stronger | $2.0M | — |
| Stockholders' EquityBook value | $5.8M | $8.0M |
| Total Assets | $18.8M | $13.5M |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.8M | ||
| Q2 25 | — | $410.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | $2.0M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | $5.8M | $8.0M | ||
| Q2 25 | $2.6M | $-54.5M | ||
| Q1 25 | $3.3M | — | ||
| Q4 24 | $12.7M | — | ||
| Q3 24 | $-23.3K | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $10.2K | — | ||
| Q4 23 | $892.8K | — |
| Q3 25 | $18.8M | $13.5M | ||
| Q2 25 | $19.3M | $11.7M | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $46.4M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $17.8M | — | ||
| Q1 24 | $17.3M | — | ||
| Q4 23 | $18.5M | — |
| Q3 25 | 0.34× | — | ||
| Q2 25 | 1.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $-6.5M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -101.6% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.8M | $-6.5M | ||
| Q2 25 | $-1.7M | $-4.8M | ||
| Q1 25 | $-3.5M | — | ||
| Q4 24 | $-617.4K | — | ||
| Q3 24 | $-640.8K | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-260.6K | — | ||
| Q4 23 | $-714.9K | — |
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-696.3K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-310.3K | — | ||
| Q4 23 | — | — |
| Q3 25 | -101.6% | — | ||
| Q2 25 | -92.6% | — | ||
| Q1 25 | -216.9% | — | ||
| Q4 24 | -40.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -82.3% | — | ||
| Q1 24 | -19.7% | — | ||
| Q4 23 | — | — |
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 3.2% | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IVF
Segment breakdown not available.
PMI
| Products | $1.1M | 94% |
| Other | $72.0K | 6% |
